Kaku A So-Armah1, Joseph K Lim2, Vincent Lo Re3, Janet P Tate4, Chung-Chou H Chang5, Adeel A Butt6, Cynthia L Gibert7, David Rimland8, Vincent C Marconi9, Matthew Bidwell Goetz10, Vasan Ramachandran11, Evan Brittain12, Michelle Long13, Kim-Lien Nguyen14, Maria C Rodriguez-Barradas15, Matthew J Budoff16, Hilary A Tindle17, Jeffrey H Samet18, Amy C Justice19, Matthew S Freiberg20. 1. Boston University School of Medicine, Boston, MA, USA. Electronic address: kaku@bu.edu. 2. Yale University School of Medicine, New Haven, CT, USA. Electronic address: joseph.lim@yale.edu. 3. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: vincentl@pennmedicine.upenn.edu. 4. Yale University School of Medicine, New Haven, CT, USA; VA Connecticut Healthcare System, West Haven, CT, USA. Electronic address: Janet.Tate2@va.gov. 5. University of Pittsburgh Schools of Medicine and Public Health, Pittsburgh, PA, USA. Electronic address: changjh@upmc.edu. 6. Weill Cornell Medical College, NY, USA; VA Pittsburgh Healthcare System, PA, USA; Hamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar. Electronic address: aab2005@qatar-med.cornell.edu. 7. VA Medical Center & George Washington University School of Medicine and Public Health, Washington, DC, USA. Electronic address: Cynthia.Gibert@va.gov. 8. Atlanta VA Medical Center & Emory University School of Medicine, Atlanta, GA, USA. 9. Atlanta VA Medical Center; Emory University School of Medicine and Rollins School of Public Health, Atlanta, GA, USA. Electronic address: vcmarco@emory.edu. 10. VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles, CA, USA. Electronic address: Matthew.Goetz@va.gov. 11. Boston University School of Medicine, Boston, MA, USA. Electronic address: vasan@bu.edu. 12. Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: evan.brittain@vumc.org. 13. Boston University School of Medicine, Boston, MA, USA. Electronic address: mtlong@bu.edu. 14. David Geffen School of Medicine at the University of California, Los Angeles, CA, USA. Electronic address: kimliennguyen@mednet.ucla.edu. 15. Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA. Electronic address: Maria.Rodriguez-Barradas2@va.gov. 16. Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Los Angeles, CA, USA. Electronic address: mbudoff@labiomed.org. 17. Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: hilary.tindle@vanderbilt.edu. 18. Boston University Schools of Medicine and Public Health, Boston Medical Center, Boston, MA, USA. Electronic address: jsamet@bu.edu. 19. VA Connecticut Healthcare System, West Haven, CT, USA; Yale University Schools of Medicine and Public Health, New Haven, CT, USA. Electronic address: Amy.Justice2@va.gov. 20. Vanderbilt University School of Medicine, Nashville, TN, USA; Nashville Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, USA. Electronic address: matthew.s.freiberg@vanderbilt.edu.
Abstract
BACKGROUND: Liver fibrosis, is independently associated with incident heart failure (HF). Investigating the association between liver fibrosis and type of HF, specifically HF with reduced ejection fraction (EF; HFrEF) or HF with preserved ejection fraction (HFpEF), may provide mechanistic insight into this association. We sought to determine the association between liver fibrosis score (FIB-4) and type of HF, and to assess whether HIV or hepatitis C status modified this association. METHODS: We included patients alive on or after 4/1/2003 from the Veterans Aging Cohort Study. We followed patients without prevalent cardiovascular disease until their first HF event, death, last clinic visit, or 9/30/2015. We defined liver fibrosis as: likely advanced fibrosis (FIB-4 > 3.25), indeterminate (FIB-4 range 1.45-3.25), unlikely advanced fibrosis (FIB-4 < 1.45). Primary outcomes were HFrEF and HFpEF (defined using ICD-9 diagnoses for HF, and EF extracted from electronic medical records using natural language processing). Cox proportional hazards models were adjusted for potential confounders and used to estimate hazard ratios (HR). RESULTS: Among 108,708 predominantly male (96%) participants mean age was 49 years. Likely advanced fibrosis was present in 4% at baseline and was associated with an increased risk of HFpEF [HR (95% confidence interval)] [1.70 (1.3-2.3)]; and non-significantly with HFrEF [1.20 (0.9-1.7)]. These associations were not modified by HIV or hepatitis C status. CONCLUSION: Likely advanced fibrosis was independently associated with incident HFpEF but not HFrEF. This suggests that risk factors and/or mechanisms for liver fibrosis may have greater overlap with those for HFpEF than HFrEF.
BACKGROUND: Liver fibrosis, is independently associated with incident heart failure (HF). Investigating the association between liver fibrosis and type of HF, specifically HF with reduced ejection fraction (EF; HFrEF) or HF with preserved ejection fraction (HFpEF), may provide mechanistic insight into this association. We sought to determine the association between liver fibrosis score (FIB-4) and type of HF, and to assess whether HIV or hepatitis C status modified this association. METHODS: We included patients alive on or after 4/1/2003 from the Veterans Aging Cohort Study. We followed patients without prevalent cardiovascular disease until their first HF event, death, last clinic visit, or 9/30/2015. We defined liver fibrosis as: likely advanced fibrosis (FIB-4 > 3.25), indeterminate (FIB-4 range 1.45-3.25), unlikely advanced fibrosis (FIB-4 < 1.45). Primary outcomes were HFrEF and HFpEF (defined using ICD-9 diagnoses for HF, and EF extracted from electronic medical records using natural language processing). Cox proportional hazards models were adjusted for potential confounders and used to estimate hazard ratios (HR). RESULTS: Among 108,708 predominantly male (96%) participants mean age was 49 years. Likely advanced fibrosis was present in 4% at baseline and was associated with an increased risk of HFpEF [HR (95% confidence interval)] [1.70 (1.3-2.3)]; and non-significantly with HFrEF [1.20 (0.9-1.7)]. These associations were not modified by HIV or hepatitis C status. CONCLUSION: Likely advanced fibrosis was independently associated with incident HFpEF but not HFrEF. This suggests that risk factors and/or mechanisms for liver fibrosis may have greater overlap with those for HFpEF than HFrEF.
Authors: Michael R Zile; Catalin F Baicu; John S Ikonomidis; Robert E Stroud; Paul J Nietert; Amy D Bradshaw; Rebecca Slater; Bradley M Palmer; Peter Van Buren; Markus Meyer; Margaret M Redfield; David A Bull; Henk L Granzier; Martin M LeWinter Journal: Circulation Date: 2015-01-30 Impact factor: 29.690
Authors: Kathleen A McGinnis; Cynthia A Brandt; Melissa Skanderson; Amy C Justice; Shahida Shahrir; Adeel A Butt; Sheldon T Brown; Matthew S Freiberg; Cynthia L Gibert; Matthew Bidwell Goetz; Joon Woo Kim; Margaret A Pisani; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Hilary A Tindle; Kristina Crothers Journal: Nicotine Tob Res Date: 2011-09-12 Impact factor: 4.244
Authors: Anthony J G Hanley; Ken Williams; Andreas Festa; Lynne E Wagenknecht; Ralph B D'Agostino; Steven M Haffner Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Olga V Patterson; Scott L DuVall; Cynthia A Brandt; Kaku A So-Armah; Ramachandran S Vasan; Kris Ann Oursler; John Gottdiener; Stephen Gottlieb; David Leaf; Maria Rodriguez-Barradas; Russell P Tracy; Cynthia L Gibert; David Rimland; Roger J Bedimo; Sheldon T Brown; Matthew Bidwell Goetz; Alberta Warner; Kristina Crothers; Hilary A Tindle; Charles Alcorn; Justin M Bachmann; Amy C Justice; Adeel A Butt Journal: JAMA Cardiol Date: 2017-05-01 Impact factor: 14.676
Authors: Adeel A Butt; Kathleen McGinnis; Maria C Rodriguez-Barradas; Stephen Crystal; Michael Simberkoff; Matthew Bidwell Goetz; David Leaf; Amy C Justice Journal: AIDS Date: 2009-06-19 Impact factor: 4.177
Authors: Olga V Patterson; Matthew S Freiberg; Melissa Skanderson; Samah J Fodeh; Cynthia A Brandt; Scott L DuVall Journal: BMC Cardiovasc Disord Date: 2017-06-12 Impact factor: 2.298
Authors: Sanyog G Shitole; Jason M Lazar; David B Hanna; Ryung S Kim; Kathryn Anastos; Mario J Garcia; Phyllis C Tien; João A C Lima; Robert C Kaplan; Jorge R Kizer Journal: AIDS Date: 2021-08-01 Impact factor: 4.632
Authors: Alan C Kwan; Janet Wei; Brian P Lee; Eric Luong; Gerran Salto; Trevor-Trung Nguyen; Patrick G Botting; Yunxian Liu; David Ouyang; Joseph E Ebinger; Debiao Li; Mazen Noureddin; Louise Thomson; Daniel S Berman; C Noel Bairey Merz; Susan Cheng Journal: Int J Cardiovasc Imaging Date: 2022-02-02 Impact factor: 2.316
Authors: Anthony E Peters; Ambarish Pandey; Colby Ayers; Kara Wegermann; Robert W McGarrah; Justin L Grodin; Manal F Abdelmalek; Tarek Bekfani; Vanessa Blumer; Anna Mae Diehl; Cynthia A Moylan; Marat Fudim Journal: ESC Heart Fail Date: 2021-02-14
Authors: Marat Fudim; Lin Zhong; Kershaw V Patel; Rohan Khera; Manal F Abdelmalek; Anna Mae Diehl; Robert W McGarrah; Jeroen Molinger; Cynthia A Moylan; Vishal N Rao; Kara Wegermann; Ian J Neeland; Ethan A Halm; Sandeep R Das; Ambarish Pandey Journal: J Am Heart Assoc Date: 2021-11-10 Impact factor: 5.501